Rogier M. Bertina

Rogier M. Bertina's AcademicInfluence.com Rankings

Rogier M. Bertina

Medical

#1542

World Rank

#1892

Historical Rank

Hematology

#19

World Rank

#22

Historical Rank

medical Degrees

Rogier M. Bertina

Law

#2021

World Rank

#2515

Historical Rank

law Degrees

Download Badge

Medical
Law

Rogier M. Bertina's Degrees

Bachelors Biomedical Sciences University of Amsterdam
Masters Biomedical Sciences University of Amsterdam
PhD Biomedical Sciences University of Amsterdam

Why Is Rogier M. Bertina Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rogier M. Bertina's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutation in blood coagulation factor V associated with resistance to activated protein C (1994) (4211)
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. (1996) (3268)
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation (1994) (1125)
Inherited Thrombophilia: Part 1 (1996) (637)
High levels of coagulation factor XI as a risk factor for venous thrombosis. (2000) (629)
Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? (2006) (462)
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. (1994) (461)
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. (2000) (398)
High levels of factor IX increase the risk of venous thrombosis. (2000) (398)
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect (1993) (371)
Prevalence of Protein C Deficiency in the Healthy Population (1995) (330)
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. (1999) (328)
Protein C Deficiency in a Dutch Family with Thrombotic Disease (1982) (310)
Inherited Thrombophilia*: Part 2 (1996) (308)
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. (1985) (300)
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. (1998) (296)
Pre-analytical and analytical issues in the analysis of blood microparticles (2010) (283)
Elevated Factor VIII Levels and the Risk of Thrombosis (2001) (282)
Increased Levels of Factor VIII and Fibrinogen in Patients with Venous Thrombosis Are not Caused by Acute Phase Reactions (1999) (271)
Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. (2005) (255)
Characterization of the Molecular Defect in Factor VR506A(*) (1995) (252)
Laboratory Diagnosis of APC-Resistance: A Critical Evaluation of the Test and the Development of Diagnostic Criteria (1994) (248)
Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. (2003) (241)
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles (2010) (240)
Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients (2012) (239)
Cryo-electron microscopy of extracellular vesicles in fresh plasma (2013) (194)
Microparticle‐associated tissue factor activity in cancer patients with and without thrombosis (2009) (194)
Protein C and the Development of Skin Necrosis During Anticoagulant Therapy (1983) (183)
Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study (1999) (181)
Resistance to Activated Protein C and Factor V Leiden as Risk Factors for Venous Thrombosis (1995) (179)
The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. (1990) (169)
Factor V Leiden: An Additional Risk Factor for Thrombosis in Protein S Deficient Families? (1995) (166)
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. (1987) (163)
Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. (1997) (158)
The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. (1991) (149)
Preeclampsia and genetic risk factors for thrombosis: a case-control study. (1999) (147)
Determination of Plasma Protein S - The Protein Cofactor of Activated Protein C (1985) (147)
Activated protein C resistance determined with a thrombin generation‐based test predicts for venous thrombosis in men and women (2003) (145)
Familial Clustering of Factor VIII and von Willebrand Factor Levels (1998) (137)
Molecular Risk Factors for Thrombosis (1999) (124)
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis (2004) (122)
ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden (2005) (121)
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma (2008) (121)
Microparticle-Associated Tissue Factor Activity: A Link between Cancer and Thrombosis?. (2005) (121)
β2-Glycoprotein I Deficiency and the Risk of Thrombosis (1992) (118)
Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. (1992) (114)
A Genetic Propensity to High Factor VII Is not Associated with the Risk of Myocardial Infarction in Men (1998) (114)
Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. (1995) (113)
Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. (1990) (113)
Hereditary Heparin Cofactor II Deficiency and the Risk of Development of Thrombosis (1987) (111)
Familial thrombophilia: a complex genetic disorder. (1997) (107)
Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk (2004) (107)
High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene (2001) (106)
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial (2001) (105)
Determinants of the APTT‐ and ETP‐based APC sensitivity tests (2005) (104)
Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation (1999) (103)
The HR2 Haplotype of Factor V: Effects on Factor V Levels, Normalized Activated Protein C Sensitivity Ratios and the Risk of Venous Thrombosis (2000) (103)
Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics (2012) (102)
Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin (1998) (102)
Hereditary Protein S Deficiency in Young Adults with Arterial Occlusive Disease (1990) (101)
Cysteine‐mutations in von Willebrand factor associated with increased clearance (2005) (101)
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. (1997) (101)
Genetic Approach to Thrombophilia (2001) (97)
The Interaction of Activated Protein C and Thrombin with the Plasminogen Activator Inhibitor Released from Human Endothelial Cells (1987) (97)
Protein C Deficiency in Two Austrian Families (1983) (95)
Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. (1996) (95)
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis (2006) (94)
G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′‐end formation (2004) (92)
Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. (1994) (92)
The 4G/5G Polymorphism in the Plasminogen Activator Inhibitor-1 Gene Is not Associated with Myocardial Infarction (1999) (90)
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). (1997) (87)
Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester (1994) (86)
The Effect of Some Instruments for Prothrombin Time Testing on the International Sensitivity Index (ISI) of Two Rabbit Tissue Thromboplastin Reagents (1989) (86)
The prothrombin 20210 G to A variation and thrombosis (1998) (84)
Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis (2002) (83)
Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography (2007) (82)
Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues (2004) (82)
ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens (2007) (79)
The Interaction of Protein S with the Phospholipid Surface Is Essential for the Activated Protein C-independent Activity of Protein S (1996) (79)
Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults (1984) (77)
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor (2008) (76)
Hemostatic Effects of Oral Contraceptives in Women who Developed Deep-vein Thrombosis while Using Oral Contraceptives (1998) (76)
Laboratory Techniques in Thrombosis — a Manual (1999) (76)
Factor X Levels, Polymorphisms in the Promoter Region of Factor X, and the Risk of Venous Thrombosis (2001) (76)
Pathways in the activation of human coagulation factor X. (1980) (74)
Two Genes Homologous with Human Protein S cDNA Are Located on Chromosome 3 (1987) (73)
Screening for the FV: Q506 Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis (1997) (73)
Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. (2010) (73)
Elevated Clotting Factor Levels and Venous Thrombosis (2003) (73)
The putative factor IX gene promoter in hemophilia B Leyden. (1988) (73)
A Frequent Thrombomodulin Amino Acid Dimorphism Is not Associated with Thrombophilia (1991) (73)
The Role of Factor VIII in the Activation of Human Blood Coagulation Factor X by Activated Factor IX (1985) (72)
Maternal TLR4 and NOD2 Gene Variants, Pro-Inflammatory Phenotype and Susceptibility to Early-Onset Preeclampsia and HELLP Syndrome (2008) (72)
The binding of aurovertin to mitochondria, and its effect on mitochondrial respiration. (1973) (71)
Lipopolysaccharide Induction of Tissue Factor in THP-1 Cells Involves Jun Protein Phosphorylation and Nuclear Factor κB Nuclear Translocation* (1999) (71)
Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. (1987) (71)
Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene (1998) (70)
Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. (2000) (70)
Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. (1984) (70)
Activated Protein C Increases Fibrin Clot Lysis by Neutralization of Plasminogen Activator Inhibitor No Evidence for a Cofactor Role of Protein S (1988) (69)
Monitoring Heparin Therapy: Relationships between the Activated Partial Thromboplastin Time and Heparin Assays Based on Ex-Vivo Heparin Samples (1990) (67)
Homzygous Protein S Deficiency due to a One Base Pair Deletion that Leads to a Stop Codon in Exon III of the Protein S Gene (1994) (66)
The Use of Desmopressin Acetate (DDAVP) as a Test of the Fibrinolytic Capacity of Patients – Analysis of Responders and Non-Responders (1982) (66)
Factor V Leiden and Fatal Pulmonary Embolism (1998) (65)
Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * (1997) (65)
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. (1986) (64)
Hereditary protein S deficiency. (1985) (63)
A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. (2001) (63)
C-Reactive Protein Does Not Directly Induce Tissue Factor in Human Monocytes (2004) (62)
Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. (1990) (62)
Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. (1987) (62)
Preeclampsia and its interaction with common variants in thrombophilia genes (2004) (61)
Hormonal State rather than Age Influences Cut-off Values of Protein S: Reevaluation of the Thrombotic Risk Associated with Protein S Deficiency (1999) (59)
Venous thrombosis--the interaction of genes and environment. (1998) (58)
Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden (2005) (57)
Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. (1998) (57)
Molecular Characterization of a Type I Quantitative Factor V Deficiency in a Thrombosis Patient that Is “Pseudo Homozygous” for Activated Protein C Resistance (1997) (57)
Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. (1991) (57)
Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. (1982) (56)
Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype). (1989) (56)
Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites (*) (1995) (55)
Polymorphisms in the Prothrombin Gene and their Association with Plasma Prothrombin Levels (2001) (55)
Fibrinogen polymorphisms are not associated with the risk of myocardial infarction (2000) (55)
The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor (2002) (54)
Monitoring Heparin Therapy by the Activated Partial Thromboplastin Time - The Effect of Pre-Analytical Conditions (1987) (54)
Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. (1996) (54)
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays (2004) (54)
Factor V Leiden: the venous thrombotic risk in thrombophilic families (2000) (54)
Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. (2006) (53)
Spectrophotometric Assays of Prothrombin in Plasma of Patients Using Oral Anticoagulants (1979) (52)
Binding of human blood-coagulation Factors IXa and X to phospholipid membranes. (1984) (52)
Protein S Deficiency Associated with “Juvenile” Arterial and Venous Thromboses (1986) (51)
Rapid Detection of the Prothrombin 20210 A Variation by Allele Specific PCR (1997) (51)
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro (1986) (50)
Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis (1994) (49)
Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation (2008) (49)
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? (2016) (48)
Two ELISA's for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency. (1990) (47)
High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden (2001) (47)
Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. (1993) (47)
Homozygosity for a Novel Missense Mutation in the Prothrombin Gene Causing a Severe Bleeding Disorder (1994) (47)
Hereditary Protein C-Deficiency: Laboratory Values in Transmitters and Guidelines for the Diagnostic Procedure Report on a Study of the SSC Subcommittee on Protein C and Protein S (1992) (46)
The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX. (1984) (46)
Fibrinogen &ggr;′ in Ischemic Stroke: A Case-Control Study (2008) (45)
Inter‐relation of coagulation factors and d‐dimer levels in healthy individuals (2003) (45)
Identification of Eight Point Mutations in Protein S Deficiency Type I – Analysis of 15 Pedigrees (1995) (45)
Partial protein S gene deletion in a family with hereditary thrombophilia (1989) (43)
Interleukin 10-2849AA genotype protects against pre-eclampsia (2004) (43)
ECAT Assay Procedures A Manual of Laboratory Techniques (2012) (42)
The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. (2005) (42)
Role of Monocytes in Experimental Staphylococcus aureus Endocarditis (2000) (42)
Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. (2010) (42)
Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency (1993) (41)
A CCA/CCG neutral dimorphism in the codon for Pro 626 of the human protein S gene PSα (PROS1) (1991) (39)
Prevalence of protein C (PC) and protein S (PS) deficiency in patients with thrombotic disease (1986) (38)
Activation of Human Coagulation Factor VIII by Activated Factor X, the Common Product of the Intrinsic and the Extrinsic Pathway of Blood Coagulation (1982) (38)
Extrinsic Activation of Human Coagulation Factors IX and X on the Endothelial Surface (1991) (38)
Diagnostic value of fibrinopeptide A and beta-thromboglobulin in acute deep venous thrombosis and pulmonary embolism. (2009) (36)
The Constitutive Expression of Anticoagulant Protein S Is Regulated through Multiple Binding Sites for Sp1 and Sp3 Transcription Factors in the Protein S Gene Promoter* (2006) (36)
The mechanism of inhibition by oligomycin of oxidative phosphorylation in mitochondria. (1974) (35)
Human protein S cDNA encodes Phe‐16 and Tyr 222 in consensus sequences for the post‐translational processing (1987) (35)
The Inhibitor of Prothrombin Conversion in Plasma of Patients on Oral Anticoagulant Treatment (1981) (35)
Scatchard plot and heterogeneity in binding affinity of labeled and unlabeled ligand. (1975) (35)
Twelve novel and two recurrent mutations in 14 Austrian families with hereditary protein C deficiency (1993) (35)
Location on the Human Genetic Linkage Map of 26 Genes Involved in Blood Coagulation (1997) (34)
Protein C and fibrinolysis: a link between coagulation and fibrinolysis. (1990) (34)
Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen γ′/γA mRNA ratio (2007) (34)
Endothelial protein C receptor polymorphisms and risk of myocardial infarction (2008) (34)
Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the Risk of Venous Thrombosis (2007) (34)
Inhibition of thrombin‐mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ′ (2013) (32)
Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. (1984) (32)
Different Sensitivities of Various Thromboplastins to Two Blood Collection Systems for Monitoring Oral Anticoagulant Therapy (1999) (32)
Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci (2003) (32)
Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. (2014) (32)
Matrix metalloproteinase-9 gene -1562C/T polymorphism mitigates preeclampsia. (2007) (31)
Alternative Splicing Is Responsible for the Presence of Two Tissue Factor mRNA Species in LPS Stimulated Human Monocytes (1992) (31)
Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction. (2009) (31)
A Plasma Coagulation Assay for an Activated Protein C-independent Anticoagulant Activity of Protein S (1998) (31)
Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk (2013) (30)
Superior Sagittal Sinus Thrombosis in a Patient Heterozygous for the Novel 20210 A Allele of the Prothrombin Gene (1998) (30)
A novel quantitative multiplex NASBA method: application to measuring tissue factor and CD14 mRNA levels in human monocytes. (1999) (30)
Determination of the allelic and haplotype frequencies of three polymorphisms in the promoter region of the human protein C gene. (1994) (30)
Tissue Factor Expression during Monocyte-Macrophage Differentiation (1997) (30)
Activated protein C accelerates clot lysis by virtue of its anticoagulant activity (1993) (29)
Functional characterization of transcription factor binding sites for HNF1‐alpha, HNF3‐beta (FOXA2), HNF4‐alpha, Sp1 and Sp3 in the human prothrombin gene enhancer (2003) (29)
The influence of thrombin and platelets on fibrin clot lysis rates in vitro: a study using a clot lysis system consisting of purified human proteins (1988) (29)
Partial protein S gene deletion in a family with hereditary thrombophilia. (1989) (29)
Studies of the Interaction between Human Protein S and Human C4b-Binding Protein Using Deletion Variants of Recombinant Human Protein S (1994) (29)
PROTEIN C CONCENTRATES FOR THERAPEUTIC USE (1982) (28)
PREVALENCE OF HEREDITARY THROMBOPHILIA AND THE IDENTIFICATION OF GENETIC RISK FACTORS (1988) (28)
Plasma fibrinogen γ′ chain content in the thrombotic microangiopathy syndrome (2007) (28)
Mutations which Introduce Free Cysteine Residues in the Gla-Domain of Vitamin K Dependent Proteins Result in the Formation of Complexes with α1-Microglobulin (1996) (28)
Protein C Deficiency and Venous Thrombosis – the Search for the Second Genetic Defect (2000) (28)
Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease (2006) (28)
The 46C→T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis (2005) (27)
Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis (1996) (27)
Role of phagocytosis in activation of the coagulation system in Streptococcus sanguis endocarditis (1996) (27)
Frequency of the TAFI –438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism (2003) (27)
Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease (2006) (26)
Functional Analysis of Two Haplotypes of the Human Endothelial Protein C Receptor Gene (2014) (26)
Plasma coagulation factor levels in venous thrombosis. (2007) (26)
Fibrinogen gamma in ischemic stroke: a case-control study (2007) (26)
A new functional assay of thrombin activatable fibrinolysis inhibitor (2005) (26)
Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. (2007) (25)
Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter* (1998) (25)
Fibrinogen gamma gene 3’-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population (2009) (25)
Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. (1998) (25)
Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. (2007) (25)
Effects of (Pre-)analytical Variables on Activated Protein C Resistance Determined Via a Thrombin Generation-based Assay (2002) (24)
The role of procoagulants and anticoagulants in the development of venous thromboembolism. (2009) (24)
Procoagulant Activity of Endocardial Vegetations and Blood Monocytes in Rabbits with Streptococcus sanguis Endocarditis (1989) (24)
A Mutation in the Protein S Pseudogene Is Linked to Protein S Deficiency in a Thrombophilic Family (1989) (24)
The Abnormal Factor IX of Hemophilia B+ Variants (1978) (24)
Thrombin, a Link between Coagulation Activation and Fibrinolysis a (1992) (23)
Factor Va Is Inactivated by Activated Protein C in the Absence of Cleavage Sites at Arg-306, Arg-506, and Arg-679* (2004) (23)
Detection of Carriers of Haemophilia B (1979) (23)
Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. (1999) (23)
Multi-Center Study of Thromboplastin Calibration Precision – Influence of Reagent Species, Composition, and International Sensitivity Index (ISI) (1993) (23)
Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. (1997) (23)
The effects of phosphate and electron transport on the carbonyl cyanide m-chlorophenylhydrazone-induced ATPase of rat-liver mitochondria. (1975) (22)
Compound Heterozygosity for One Novel and One Recurrent Mutation in a Thai Patient with Severe Protein S Deficiency (1999) (22)
Extrinsic Activation of Human Blood Coagulation Factors IX and X (1990) (22)
Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction (2006) (22)
Preparation of a human factor VII deficient plasma. (1978) (22)
Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart". (1999) (22)
Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin (1993) (22)
Affinities of ATP for the dinitrophenol-induced ATPase. (1973) (21)
A Genetic Variant of Factor IX with Decreased Capacity for Ca2+ Binding (1979) (21)
Protein C Antigen Levels in Major Abdominal Surgery: Relationships to Deep Vein Thrombosis, Malignancy and Treatment with Stanozolol (1985) (21)
Prothrombin Time Ratio Is Reduced by Magnesium Contamination in Evacuated Blood Collection Tubes (2001) (21)
A Second Plasma Inhibitor of Activated Protein C: α1-Antitrypsin (1989) (21)
Inhibitor-neutralisation assay and electro-immuno assay of human factor IX (Christmas factor). (1977) (21)
Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. (1982) (21)
Immunoradiometric assay of procoagulant factor VIII antigen (VIIICAG). (1980) (20)
Multi-Center Calibration of the Second Reference Material for Thromboplastin, Rabbit, Plain, Coded CRM 149R (1991) (20)
Genome‐wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis study (2013) (20)
The human protein S locus: identification of the PS alpha gene as a site of liver protein S messenger RNA synthesis. (1988) (20)
Haplotypes encoding the factor VIII 1241Glu variation, factor VIII levels and the risk of venous thrombosis (2006) (20)
Cholesterol or triglyceride loading of human monocyte-derived macrophages by incubation with modified lipoproteins does not induce tissue factor expression. (1999) (20)
The −589C>T polymorphism in the interleukin‐4 gene (IL‐4) is associated with a reduced risk of myocardial infarction in young individuals (2008) (20)
Coagulation Factors in the Human Fetus of about 20 Weeks of Gestational Age (1980) (20)
Construction and Characterization of Thrombin-resistant Variants of Recombinant Human Protein S (1994) (20)
venous thrombosis Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of (2013) (19)
The Role of Factor IX in Tissue Thromboplastin Induced Coagulation (1982) (19)
A Novel Serine Protease Secreted by Medicinal Maggots Enhances Plasminogen Activator-Induced Fibrinolysis (2014) (19)
The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model (2002) (19)
Multicenter Evaluation of Three Commercial Methods for Measuring Protein S Antigen (1992) (19)
The HR2 Haplotype of Factor V Is not Associated with the Risk of Myocardial Infarction (2000) (19)
Laboratory Diagnosis of Resistance to Activated Protein C (APC-resistance) (1997) (19)
The Endothelial Protein C Receptor (EPCR) 23 bp Insert Mutation and the Risk of Venous Thrombosis (2002) (18)
A Variant of Factor X That Is Defective Only In Extrinsic Coagulation (1981) (18)
Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. (1995) (18)
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation (1996) (17)
Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. (1998) (17)
Prothrombin 20210A Variant and Age at Thrombosis (1998) (17)
The Functional Defect of Factor VIII Leiden, a Genetic Variant of Coagulation Factor VIII (1985) (16)
Microparticles expressing tissue factor are concurrently released with markers of inflammation and coagulation during human endotoxemia (2012) (16)
Protein C inhibitor (plasminogen activator inhibitor‐3) and the risk of venous thrombosis (2002) (16)
Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis (2008) (16)
Factor IXa protects activated factor VIII against inactivation by activated protein C. (1984) (16)
Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation (2008) (16)
Expression and Characterization of Recombinant Human Protein S in Heterologous Cells - Studies of the Interaction of Amino Acid Residues Leu-608 to Glu-612 with Human C4b-Binding Protein (1992) (16)
Candidate gene approach in association studies: would the factor V Leiden mutation have been found by this approach? (2004) (15)
Antigenic and Functional Expression of Tissue Factor in Endotoxin Stimulated U937 Cells: Regulation of Activity by Calcium Ionophore A23187 (1995) (15)
Rabbit Polyclonal Antibodies Against the Calcium-Dependent Conformation of Factor IX and Their Application in Solid Phase Immunoradiometric Assays (1986) (15)
New method for the rapid detection of vitamin k deficiency. (1980) (15)
Factor IX Deventer-Evidence for the Heterogeneity of Hemophilia BM (1982) (15)
Inherited Prethrombotic Disorders and Infectious Purpura (1996) (15)
Laboratory Techniques in Thrombosis. A Manual: 2nd revised edition of ECAT Assay Procedures (1999) (14)
Compound Heterozygosity for Two Novel Missense Mutations in the Prothrombin Gene in a Patient with a Severe Bleeding Tendency (1997) (14)
The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181 (2003) (14)
Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma. (2014) (14)
Coagulation factors in the premature infant born after about 32 weeks of gestation. (1985) (14)
Protein C (PC) and coumarin-induced skin necrosis (1986) (14)
Fibrinogen γ′ in Ischemic Stroke (2008) (13)
Application of Two Neutral Mspl DNA Polymorphisms in the Analysis of Hereditary Protein C Deficiency (1990) (13)
Discovery of thrombin activatable fibrinolysis inhibitor (TAFI) (2006) (13)
Role of Monocytes and Bacteria inStaphylococcus epidermidis Endocarditis (1998) (13)
A one-year follow-up study of plasma fibrinopeptide A and beta-thromboglobulin after deep vein thrombosis and pulmonary embolism. (1982) (12)
Factor IX-R338L (Factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. (2011) (12)
Application of factor VII-Sepharose affinity chromatography in the purification of human tissue factor apoprotein. (1986) (12)
Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR (1996) (12)
A second plasma inhibitor of activated protein C: alpha 1-antitrypsin. (1989) (12)
Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity (1999) (12)
Simplified procedure for the assay of fibrinopeptide A in plasma. (1981) (12)
Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients. (2013) (12)
Functional analysis of two prothrombin 3′‐untranslated region variants: the C20209T variant, mainly found among African‐Americans, and the C20209A variant (2006) (12)
Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation. (1995) (11)
Genetic aspects of venous thrombosis. (2001) (11)
Protein C activation by an activator purified from the venom of Agkistrodon halys halys (1993) (11)
An International Collaborative Study on the Performance of Protein C Antigen Assays (1987) (11)
Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene. (1994) (11)
Interleukin-6 Induction of Protein S Is Regulated Through Signal Transducer and Activator of Transcription 3 (2006) (11)
Plasma beta-thromboglobulin and platelet factor 4 in renal failure. (1981) (11)
Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels (2010) (11)
Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa. (1997) (10)
A CCA/CCG neutral dimorphism in the codon for Pro 626 of the human protein S gene PS alpha (PROS1). (1991) (10)
Immunoradiometric Assays for Human Coagulation Factor VII Using Polyclonal Antibodies Against the Ca(II)-Dependent and Ca(II)-Independent Conformation (1986) (10)
Specificity of protein C and protein S assays (1990) (10)
Severe Deep Vein Thrombosis in a 2-Year-Old Child with Protein S Deficiency (1987) (10)
Carrier Detection of Haemophilia B by Using an Intragenic Restriction-Fragment Length Polymorphism (1985) (10)
Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight. (1982) (10)
Initiation of Protein S mRNA synthesis in human liver and various cell lines (2005) (9)
C825T polymorphism in the human G protein beta 3 subunit gene and preeclampsia; a case control study. (2004) (9)
A SECOND INHIBITOR OF ACTIVATED PROTEIN C (APC) (1987) (9)
Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII. (1999) (8)
Localization of transcription initiation sites in the human coagulation factor IX gene (1990) (8)
Two Mutations of the Factor IX Gene Including a Donor Splice Consensus Deletion and a Point Mutation in a Dutch Patient with Severe Hemophilia B (1990) (8)
Functional analysis of two polymorphisms in the 3′‐UTR of the human prothrombin gene (2005) (8)
STIMULATION OF FIBRINOLYSIS BY ACTIVATED PROTEIN C (APC) (1987) (8)
A Monoclonal Anti Human Factor Ix Produced By A Mouse Hybridoma (1981) (8)
Immunologic studies on the relationship between FVIII related antigen and FVIII procoagulant activity. (1980) (7)
Protein S antigen (1999) (7)
Haemostatic effects of stanozolol in elderly medical patients. (1984) (7)
Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies. (1998) (7)
Increased Lipoprotein ( a ) levels are not a steady prothrombotic defect (2001) (7)
Identification of Evolutionarily Invariant Sequences in the Protein C Gene Promoter (1998) (7)
The Potential Use of Chromogenic Assays in the Routine Monitoring of Oral Anticoagulant Therapy (1980) (7)
Protein C and related proteins : biochemical and clinical aspects (1988) (7)
Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. (1998) (7)
Use of immuno-magnetic beads for direct capture of nanosized microparticles from plasma (2012) (6)
Tissue Factor-Induced Coagulation Can Be Inhibited by Aprotinin (Trasylol) (1993) (6)
Ecat Assay Procedures (a manual of laboratory techniques): European concerted action on thrombosis and disabilities of the commission of the European Communities (1993) (6)
Immunoradiometric Assay for the Calcium-Stabilized Conformation of Human Protein S (1987) (6)
The risk of thrombosis in hereditary protein S deficiency in a Scandinavian family (1989) (6)
The R306G and R506Q mutations in coagulation Factor V reveals additional cleavage sites for Activated Protein C in the R313-R321 region and at R505. (2010) (6)
Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity. (1999) (6)
MspI RFLP in intron 8 of the human protein C gene. (1989) (5)
Two RFLPS ˜ 7kb 5′ of the human protein C gene (1988) (5)
A Dutch pedigree with mild hemophilia B with a missense mutation in the first EGF domain (factor IXOud en Nieuw Gastel). (1989) (5)
Preeclampsia and the C282Y mutation in the hemochromatosis (HFE) gene. (2004) (5)
Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a ‘procoagulant state': effects of bezafibrate therapy (2001) (5)
Haplotypes of IL 1 B , IL 1 RN , IL 1 R 1 , and IL 1 R 2 and the Risk of Venous Thrombosis (2007) (5)
Heterogeneity of haemophilia A: a study with three different antisera (1982) (5)
Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels (2012) (5)
A Dutch family with moderately severe hemophilia B (factor IXHeerde) has a missense mutation identical to that of factor IX London 2. (1989) (5)
Plasma levels of von Willebrand factor, von Willebrand factor propeptide and factor VIII in carriers and patients with nephrogenic diabetes insipidus. (2010) (5)
Critical appraisal, clinical usefulness, and implementation of the thromboplastin concept of prothrombin-time standardization. (2009) (4)
Thrombomodulin activity in commercial thromboplastin preparations. (1986) (4)
List of manufacturers (1992) (4)
The Relationship Between the International Normalized Ratio and the Coumarin-Induced Coagulation Defect (1984) (4)
Negatively charged phospholipids stimulate factor XI activation by thrombin (2021) (3)
Plasma Fibrinopeptide A and Beta-Thromboglobulin in Major Bacterial Infections (1982) (3)
Molecular basis of hereditary protein C and protein S deficiency. (1991) (3)
USE OF COAGULATION ASSAYS IN PRENATAL DIAGNOSIS OF HAEMOPHILIA A AND B (1981) (3)
FACTOR V LEIDEN, ET AL. FACTOR MUTATIONS AFFECTING THROMBOTIC RISK (1997) (3)
Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII (2008) (3)
Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V (2004) (3)
Genetic variants of factor ix (1981) (3)
Immunoradiometric assays for the Ca(II)-dependent and Ca(II)-independent conformation of human protein C. (1988) (3)
[High concentration of coagulation factor VIII as a risk factor for thrombosis]. (2001) (3)
Polymorphism 10034C>T Is Located in a Functional Cleavage Stimulation Factor (CstF) Binding Site of the Fibrinogen Gamma Gene and Influences the γ′/γA mRNA Ratio. (2006) (3)
Functional Assays of Plasma Protein C (1985) (2)
Protein C activity and antigen (1999) (2)
INDEPENDENT ISOLATION OF HUMAN PROTEIN S cDNA AND THE ASSIGNMENT OF THE GENE TO CHROMOSOME 3 (1987) (2)
The usefulness of single‐strand DNA conformation polymorphism analysis to detect mutations in protein C deficiency (1997) (2)
Proteolysis of blood coagulation factor X by activated factor X (1982) (2)
Deep-vein thrombosis is not associated with the P/S186 polymorphism of histidine-rich glycoprotein (1999) (2)
Variants of Vitamin K Dependent Coagulation Factors (1979) (2)
A Pstl RFLP of the LACl gene (1990) (2)
Activation of Normal and Abnormal (Genetic Variant) Human Factor IX (1979) (2)
Involvement Of Human Factor IX In Tissue Thromboplastin Induced Coagulation (1981) (2)
Partial Reconstitution of Factor VIII Activity from a Mild Crm+ Hemophilia A Patient by Replacement of the Defective A2 Domain (1998) (2)
CONSIDERATIONS ON THE TRUE VALUE OF THE INTERNATIONAL NORMALIZED RATIO IN THE CONTROL OF ORAL ANTICOAGULANT THERAPY (1994) (2)
Carrier Detection in Hemophilia B. (1977) (1)
A PstI RFLP of the LACI gene. (1990) (1)
Is the prothrombin 19911A>G polymorphism a functional noncoding variant? (2005) (1)
Maggot secretions enhance plasminogen activator-induced fibrinolysis by cleavage of plasminogen (2009) (1)
More Than One Type of Factor X in Plasma of Patients Using Oral Anticoagulants (1982) (1)
DEFECTS OF VITAMIN K-DEPENDENT FACTORS IN CA(11)-STABILI ZED STRUCTURE (1987) (1)
PROMOTOR MUTATIONS IN A PATIENT WITH HAEMOPHILIA B LEYDEN (1987) (1)
IS THE ACTIVITY OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) OF CLINICAL RELEVANCE IN THROMBOPHILIA CAUSED BY PROTEIN S DEFICIENCY? (1988) (1)
Monitoring of oral anti coagulant therapy by chromogenic methods an evaluation of the present impossibilities (1983) (1)
The effect of factor V Leiden, oral contraceptive use, type of oral contraceptives and pregnancy on APC-r levels in women with or without a history of pre-eclampsia. (2001) (1)
Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphy1ocoagulase complex, associated with thrombotic episodes (1985) (1)
Factor Va is inactivated by APC in the absence of cleavage sites at Arg 306 , Arg 506 and Arg 679 (2003) (1)
Fibrinopeptide A And Beta-Thromboglobulin Concentrations In Venous And Arterial Disorders (1981) (1)
129 Activated protein C increases fibrin clot lysis (purified system) by inactivating plasminogen activator inhibitor; No evidence for a cofactor role of protein S (1988) (1)
Inhibition of tissue type plasminogen activator inhibitor activity by activated protein C: abstract (1984) (1)
FIBRINOLYTIC ACTIVITY IN PROTEIN S DEFICIENCY (1988) (1)
Over 50% of Dutch VTE families with protein C deficiency share a founder R272C mutation (2011) (1)
Hereditary deficiency in heparin cofactor II (HeCoFII) and the risk for the development of thrombosis (1986) (1)
Solid phase immunoradiometric assay of activated human coagulation factor IX. (1987) (1)
52 Profibrinolytic activity associated with anti-coagulation (1988) (1)
The effect of plasma caeruloplasmin levels on the sensitivity for activated protein C (2002) (1)
Two RFLPS approximately 7 kb 5' of the human protein C gene. (1988) (1)
Results Effect of CRP and LPS on TF Antigen Expression of Purified Human Monocytes in Culture (2004) (0)
Haplotypes encoding th ef actor VIII 1241Glu variation ,f actor VIII levels an dt he ris ko fv enous thrombosi s (2006) (0)
Secretion of fibrinolysis components and factor VIII related antigen by cultured endothelial cells from human aorta and vena cava: abstract (1984) (0)
X-Linked Coagulation Disorders (1984) (0)
Cryo-electron microscopy of submicron particles in plasma (2011) (0)
IMMUNOLOGICAL ASSAYS FOR THE Ca(II)-DEPENDENT AND NONCa(II)-DEPENDENT CONFORMATIONS OFJtLUMAN PROTELN Z (PZ) (1987) (0)
Contents Vol. 33 (2003) (0)
Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics (2012) (0)
EXTRINSIC ACTIVATION OF HUMAN COAGULATION FACTORS IX AND X ON THE ENDOTHELIAL SURFACE (1987) (0)
Microparticles, the missing link between cancer and thrombosis? (2006) (0)
8 Microparticle-associated tissue factor activity , venous thrombosis and poor survival in pancreatic cancer patients (2008) (0)
Method of thrombosis and / or poor antikoagulanttivasteeseen activated protein C in the presence of the mutation of screening (1995) (0)
fhe4G/5G Polymorphism in the Plasminogen Activator Inhibitor-1 Gene Is not Associated with Myocardial Infarction (2005) (0)
Hemostatic parameters do not predict restenosis after coronary angioplasty (1995) (0)
[Search for the carrier state of hemophilia B using restriction fragment length polymorphism]. (1985) (0)
Factor VII Activity and Antigen in Haemophilia B Variants (1980) (0)
C0069 Association of haplotypes (H) 1 and 3 of the endothelial protein c receptor gene (PROCR) with venous thromboembolism (2012) (0)
Screening of eleven candidate genes from the 7p21.3 and Xq25 q26.3 linkage regions for association with venous thromboembolic risk: results from The Genetics In Familial Thrombosis (GIFT) Study (2009) (0)
The detection of tissue factor bearing-microparticles by atomic force microscopy (2011) (0)
Atomic Force Microscopy and the Detection of Nanosized Blood Microparticles (2011) (0)
Alterations in the tissue factor pathway in hypertriglyceridemia do not cause a “pro-coagulant state”; Effects of lipid lowering therapy by bezafibrate (2000) (0)
A method of screening for the presence of a genetic defect associated with thrombosis and / or poor anticoagulate (1995) (0)
Detection, Purification and Comparison of Factor IX-Like Molecules (1977) (0)
The Effect of Some lnstruments for Prothrombin Time (2005) (0)
C0121: In Vitro Functional Analysis of the H1 Haplotype of the Human Endothelial Protein C Receptor Gene (PROCR) (2014) (0)
No Malabsorption of Inorganic Ferrous Iron in Patients with Achylia gastrica (1979) (0)
Leiden Increases the Risk of Venous Thrombosis A Reduced Sensitivity for Activated Protein C in the Absence of Factor V (2013) (0)
Enhancement of protein C by stanozolol in healthy adults and in surgical patients : abstract (1983) (0)
A novel genetic risk factor for venous thrombosis. (2011) (0)
A method for detecting a genetic defect, assoziert with thrombosis and / or poor anticoagulant response to activated protein C (1995) (0)
C0068 Haplotypes of the endothelial protein C receptor gene and circulating protein C levels (2012) (0)
C0076 The endothelial protein C receptor is essential for protein C activation in vivo (2012) (0)
endothelial cell-conditioned medium Activated protein C decreases plasminogen activator-inhibitor activity in (2011) (0)
The Contribution Of Factor VIII In The Intrinsic Activation Of Human Factor X (1981) (0)
The Prothrombotic Polymorphism Prothrombin G20210A Is an Ancestral Mutation That Arose in Caucasians Approximately 20,000 Years Ago. (2005) (0)
Hereditary protein C deficiency in symptomatic families: Individuals with the genetic defect have an increased risk for venous thrombotic events (1992) (0)
7 Case – control study identifying microparticle-associated tissue factor activity as a biomarker of cancer-specific thrombosis (2008) (0)
Microparticle-associated tissue factor activity is associated with disease severity in patients with E. coli urosepsis (2013) (0)
Genetic variation in the ﬁbrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma ﬁbrinogen (cid:1)(cid:2) levels (2005) (0)
2016 Reviewer Acknowledgment (2017) (0)
Non-Functional FVIII Measured in a Group of Haemophilia a Patients with a Homologous and Heterologous Anti VIII:C Serum (1979) (0)
A method for the presence of a genetic defect associated with thrombosis and / or poor anticoagulant response to activated protein c. (1995) (0)
Atherosclerosis and apoptosis; the role of p53 and CD95L (2001) (0)
CLINICAL High levels of factor IX increase the risk of venous thrombosis (2005) (0)
[New risk factors in the development of venous thrombosis]. (1985) (0)
The Relation Between VIIIR:AG and VIII:C Studied with two Antisera (1979) (0)
phenotype) expression of blood coagulation factor IX (hemophilia B Leyden Two novel point mutations correlate with an altered developmental (2011) (0)
Definition And Evaluation Of A Therapuetic Range For The Control Of Oral Anticoagulant Treatment By Chromogenic Assays (1981) (0)
RESTRICTION ANALYSIS AND SOUTHERN BLOTTING OF TOTAL HUMAN DNA REVEALS THE EXISTENCE OF MORE THAN ONE GENE HOMOLOGOUS WITH PROTEIN S cDNA (1987) (0)
A Genetic Variant Gf Factor IX With An Abnormal High Molecular Weight (1981) (0)
The Effect of Aquaporin 2 Gene Variations on Plasma Levels of von Willebrand Factor and Factor VIII and on the Risk of Venous Thrombosis. (2007) (0)
[Molecular basis of hereditary thrombophilia]. (1997) (0)
Associations of Blood Pressure and Antihypertensive Drugs with Plasma Levels of Coagulation Factor VIII (2008) (0)
C0116: Functional Analysis of Two Haplotypes of the Human Endothelial Protein C Receptor Gene (PROCR) (2014) (0)
12 Protein S andgen (1992) (0)
The Mechanism of Activation of Human Coagulation Factor X (1979) (0)
Prothrombin 20210A Variant and Age at Thrombosis (1998) (0)
Role of coagulation activation in lysability of fibrin clots (1990) (0)
by activated protein C in vitro The cofactor role of protein S in the acceleration of whole blood clot lysis (2011) (0)
Use of immuno-magnetic beads for direct capture of nanosized blood microparticles from plasma (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rogier M. Bertina?

Rogier M. Bertina is affiliated with the following schools:

Rogier M. Bertina's Academic­Influence.com Rankings

Rogier M. Bertina's Degrees

Why Is Rogier M. Bertina Influential?

Rogier M. Bertina's Published Works

Published Works

What Schools Are Affiliated With Rogier M. Bertina?

Rogier M. Bertina's AcademicInfluence.com Rankings